Alerta

METHOD FOR IDENTIFYING A MULTI-PARAMETER PHENOTYPE OF MICROBIOTA

Resumen de: US20260227396A1

0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.

METHODS FOR PRODUCING HIGH-LEVEL SQUALENE

Resumen de: US20260226485A1

0000 Aspects of the present disclosure relate to modified yeast cells capable of producing increased quantities of squalene as compared to unmodified yeast cells and methods of using the same.

COMPOSITIONS AND METHODS FOR CONTROLLING PATHOGENS AND IMPROVING HYGIENE IN THE POULTRY AND LIVESTOCK INDUSTRIES

Resumen de: WO2026165108A1

The present inventive concept provides methods using non-toxic compositions that include components selected from ethanol, polymers, polar aprotic solvents, water, organic acids, phospholipids, polyols, polysaccharides, phenols, plant extracts, organic salts, peroxide, and peptide antibiotics designed as hygienic agents for the poultry and livestock industries. The compositions and methods provide a safer alternative to use of traditional formaldehyde (e.g., aldehyde-based) compositions by incorporating non-toxic preservation and antimicrobial agents to enhance biosecurity and sanitation in the livestock environments, and in particular, poultry production environments. The methods provided herein also control the growth of pathogenic bacteria such as Salmonella, Campylobacter, Streptococcus, Staphylococcus, E. coli, Clostridia, and Bacillus. Moreover, the methods and compositions provide safer working conditions by eliminating workers' exposure to carcinogenic substances.

COMPOSITIONS AND METHODS FOR ENHANCING ANIMAL FEED SAFETY AND CONTROLLING PATHOGENS

Resumen de: WO2026165105A1

The present inventive concept provides non-toxic compositions that include components selected from ethanol, polymers, polar aprotic solvents, water, organic acids, phospholipids, polyols, polysaccharides, phenols, plant extracts, organic salts, peroxide, and antibiotics. The compositions are designed as an enhancement or additive to animal feed additives, animal feedstuff, animal feed, or animal hydration sources. The compositions provide a safer alternative to traditional formaldehyde (e.g., aldehyde-based) compositions by incorporating preservative and antimicrobial agents into animal feed products. The compositions provided herein render animal feed highly resistant to recontamination by pathogenic bacteria such as Salmonella, Campylobacter, Streptococcus, Staphylococcus, E. coli, Clostridia, and Bacillus. Moreover, the compositions provide safer working conditions by eliminating workers' exposure to carcinogenic substances.

IN OVO VACCINATION OF GENETICALLY MODIFIED SALMONELLA VECTORED VACCINES

Resumen de: WO2026165563A1

Disclosed are methods for inoculating embryonated avian eggs for conferring protective immune responses against diseases caused by a diversity of bacterial, viral and parasite pathogens. According to certain aspects methods are disclosed that involve administering, in ovo, a safe inoculating dose of a Protective Immunity Enhanced Salmonella Vaccine (PIESV) strain, or derivative thereof, and optionally co-administering a safe inoculating dose of a live self-destructing attenuated adjuvant Salmonella strain (SDAAS), or derivative thereof.

BIOSENSOR MATERIALS

Resumen de: US20260227395A1

0000 The disclosure provides a three-dimensional (3-D) macroporous melamine foam membrane comprising an amine reactive group. The membrane foam can be used to perform ELISA assays for the detection of an analyte. Diffusion of the analyte through the different membrane layers is fast and homogeneous in all directions and suitable for detection of large volume of samples in low concentration of targets and multiple targets simultaneously in one integrated system with minimal interference from targets.

一种具有免疫增强功能的蛋白、其编码基因及应用

Resumen de: CN122502457A

本发明公开了一种具有免疫增强功能的蛋白、其编码基因及应用。本申请所述具有免疫增强功能的蛋白的氨基酸序列如SEQ ID NO.1所示。该蛋白取自鼠伤寒沙门菌鞭毛蛋白FliC的C端部分序列，不仅保留了鞭毛蛋白固有的免疫增强活性，还显著降低了其免疫原性；将其应用于含铝佐剂的猪圆环病毒2型亚单位疫苗时，可有效增强该疫苗的免疫原性，诱导体液和细胞免疫应答，并显著促进抗原特异性的Th1和Th2型免疫应答，对完善现有含铝佐剂亚单位疫苗的配方、提升疫苗免疫效果具有重要意义。

基于噬菌体展示技术筛选的沙门菌模拟抗原表位肽及应用

Resumen de: CN122502436A

本发明适用于微生物技术领域，提供了一种基于噬菌体展示技术筛选的沙门菌模拟抗原表位肽及应用，其中，该沙门菌模拟抗原表位肽能够与抗沙门菌的多克隆抗体特异性结合，其包括如序列表SEQ ID NO:1‑4所示的一种或多种氨基酸序列。本发明筛选的沙门菌模拟抗原表位肽能特异性结合抗沙门菌的多克隆抗体，显著诱导机体体液免疫和细胞免疫应答，并对多种沙门菌血清型及产肠毒素大肠杆菌可以产生交叉保护，攻毒存活率高，安全性好。本发明为由革兰氏阴性病原体引起的疾病的预防和治疗提供了一种全新的有效疫苗。

METHODS AND CONSTRUCTS FOR IMPROVING CONJUGATION EFFICIENCY

Resumen de: US20260218209A1

The present invention is directed to a method for increasing conjugation efficiency of a basic conjugative element by inserting into the leading region sequence of the conjugative element an anti-defense nucleotide sequence encoding at least one anti-defense gene.

KIT FOR IDENTIFYING ANTIMICROBIAL AGENTS AND EFFECTIVE CONCENTRATIONS THEREOF

Resumen de: US20260219269A1

0000 A method and kit for for determining of an effective concentration of an antimicrobial agent for inhibiting bacterial growth are provided. The method and kit involve the use of a first and second multiwell receptacle. A fluid sample containing or suspected to contain one or more microbial organisms is dispensed into the wells of the first multiwell receptacle containing a range of dilutions of an antimicrobial agent, growth medium and a bacteriophage to form assay mixtures in the wells. The assay mixtures are then transferred to the corresponding wells of the second multiwell receptacle for detection.

TUMOR-TARGETING PHARMACEUTICAL COMBINATIONS

Resumen de: US20260216257A1

0000 A pharmaceutical combination and uses thereof, wherein the pharmaceutical combination comprises a tumor-homing bacteria and a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant.

PATHOGENIC SENSING, DIFFERENTIATION AND QUANTIFICATION PLATFORMS

Resumen de: WO2025064651A1

A sensor-enabled pathogen identification, differentiation, and quantification system that integrates into supply chains in an end-to-end fashion and is built on a multi-source, multi-sectoral data environment. The system uses portable sensing platforms that are easily integrated at multiple points along a supply chain and which integrate sample analysis and data processing such that all necessary work can be performed on-site and/or via wireless data transfer.

ワクチン

Resumen de: WO2025021712A1

The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.

BACTERIOPHAGES AND USE THEREOF FOR THE TREATMENT OR PREVENTION OF INFECTION CAUSED BY SALMONELLA GALLINARUM

Resumen de: US20260207687A1

0000 A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.

志賀毒素産生大腸菌及び／又は腸管出血性大腸菌を検出及び確認するための方法

Resumen de: WO2025003119A1

The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.

一种α和ε型产气荚膜梭菌的融合蛋白、亚单位疫苗组合物及其应用

Resumen de: CN122427295A

本发明涉及生物技术、动物防疫领域，具体涉及一种α和ε型产气荚膜梭菌的融合蛋白、亚单位疫苗组合物及其应用。本发明通过将产气荚膜梭菌ε蛋白片段、产气荚膜梭菌α蛋白片段、鼠伤寒沙门氏菌鞭毛蛋白片段利用柔性连接肽顺序连接，构建得到了一种无毒力、安全性高、能够有效刺激机体产生抗体的融合蛋白，其氨基酸序列如SEQ ID NO:13所示。该融合蛋白经大量分泌表达后，蛋白含量不低于575μg/mL，蛋白纯度不低于87%。本发明进一步以融合蛋白为抗原，制备得到了一种能够同时预防产气荚膜梭菌α毒素和ε毒素引起的疾病的亚单位疫苗组合物，其制备方法简单、生产成本低，免疫效果好，具有高效的中和与攻毒保护能力，持久免疫应答能力，同时质量稳定、安全性高。

Synthetic binding agents for limiting permeation through mucus

Resumen de: AU2026205168A1

Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents. un u n

ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA

Resumen de: US20260201361A1

0000 The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharmaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.

EXPRESSION OF ANTIGEN-ADJUVANT FUSION SUBUNIT PROTEINS IN DIATOMS, AND METHODS OF GENERATION AND USE THEREOF

Resumen de: US20260200994A1

This application relates to compositions and methods used to treat animals with at least one microbial protein, such as a flagellin protein. In embodiments, application relates to compositions and methods to treat animals with a fusion protein comprising at least one adjuvant protein, such as a flagellin protein. In embodiments, the composition further includes at least one adjuvantic protein fused with at least one antigen protein, and the fusion protein is expressed in diatoms.

一种预防幽门螺杆菌感染的组合物及制备方法和应用

Resumen de: CN122351451A

本发明提供了一种预防幽门螺杆菌感染的组合物及制备方法和应用。所述组合物包括外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液；所述外膜囊泡混合物由沙门菌突变株QS0074的外膜囊泡和大肠杆菌E. coli Nissle 1917的外膜囊泡按照重量比2:1组成；所述外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液的重量体积比为1mg:1mL。本发明所得组合物在攻毒试验中，显著优于对照组，具有高效的预防幽门螺杆菌感染的效果。同时，本发明的组合物各组分之间在诱导小鼠产生分泌性IgA水平和分泌性IgA水平以及诱导小鼠产生抵抗幽门螺杆菌感染能力方面，均产生了明显的协同作用，具有良好的应用前景。

MICROBIALS FOR SALMONELLA INHIBITION

Resumen de: WO2026148245A1

The present disclosure relates to microbials for use in E. coli, Salmonella, Enterococcus and/or Clostridium inhibition in animals and their environment. More particularly, the present disclosure relates to isolated Bacillus strains MDG-844 (NRRL No. B-68469), MDG-UF7 (NRRL No. B-68470), MDG-UC25 (NRRL No. B-68471), and MDG-I60 (NRRL No. B-68472), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

PORCINE INTERFERON-LIKE RECOMBINANT PROTEIN AND USE THEREOF

Resumen de: US20260191946A1

This invention relates to the field of biomedicine and specifically to a porcine interferon-like recombinant protein and its applications. By constructing and screening a PoIFN-α DNA shuffling bacterial library, a highly active recombinant protein Porferon was obtained. Porferon exhibits potent anti-infective activity against a broad range of porcine pathogens, including viruses, bacteria, and parasites. Its biological activity is significantly superior to that of natural porcine interferon. As such, Porferon can be used in the development of therapeutics for the prevention or treatment of infectious diseases in pigs, offering a novel and effective solution for clinical applications in veterinary medicine.

志賀毒素産生大腸菌及び／又は腸管出血性大腸菌を検出するための反応培地及び方法

Resumen de: WO2025003117A1

The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.

Preparation method of chitosan antibacterial film, prepared antibacterial film and application

Resumen de: CN122325803A

The invention discloses a chitosan antibacterial film preparation method, which comprises: respectively preparing a berberine aqueous solution and a tannic acid aqueous solution, dropwise adding the berberine aqueous solution into the tannic acid aqueous solution to form a mixed solution, stirring and heating the mixed solution to obtain a suspension, and freeze-drying the suspension to obtain berberine-tannic acid nanoparticles; and mixing an acetic acid aqueous solution of chitosan with the berberine-tannic acid nanoparticles, and forming a film to obtain the chitosan antibacterial film loaded with the berberine-tannic acid nanoparticles. The prepared chitosan antibacterial film is low in moisture content and swelling degree, strong in ultraviolet shielding force and high in transparency, has relatively strong inhibitory activity on staphylococcus aureus and salmonella typhimurium, and can better meet the food fresh-keeping requirement.

Feed additive for reducing antibiotic resistance genes in animal waste as well as preparation method and application of feed additive

Nº publicación: CN122320124A 03/07/2026

Solicitante:

ANHUI SCIENCE AND TECHNOLOGY UNIV
\u5B89\u5FBD\u79D1\u6280\u5B66\u9662

Resumen de: CN122320124A

The invention belongs to the technical field of feed additives, and particularly relates to a feed additive for reducing antibiotic resistance genes in animal waste as well as a preparation method and application of the feed additive. The feed additive comprises the following components in percentage by mass: 10%-15% of rosmarinic acid, 10%-15% of 5-O-caffeoylshikimic acid, 8%-12% of herba lycopi flavone, 7%-10% of tea polyphenol, 7%-10% of DL-alpha-tocopherol, 22%-28% of hydroxypropyl-beta-cyclodextrin, 18%-22% of a microcapsule wall material, 0.8%-1.2% of EDTA-2Na (Ethylene Diamine Tetraacetic Acid) and 1.5%-2.2% of a citric acid-sodium citrate buffer solution. The feed additive disclosed by the invention not only has definite bacteriostatic activity on escherichia coli and salmonella, but also can improve the growth performance of weaned piglets, reduce the diarrhea rate of the weaned piglets and the abundance of drug-resistant genes in excrement of the weaned piglets, and has a good application prospect.